NDA 211710 · Bayer Healthcare
Vitrakvi
Larotrectinib Sulfate · Oral · Kinase Inhibitor
Breakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Apr 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Nov 26, 2018
Approved uses
3
Original approval plus efficacy supplements
Registered trials
21
0 Phase 3, 8 recruiting
FAERS reports
896
668 serious, 163 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 22, 2026.
VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Select patients for therapy based on an FDA-approved test [see Dosage and Administration (2.1) ]. VITRAKVI is a kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that: have a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Select patients for therapy based on an FDA-approved test. ( 1 , 2.1 )
Mechanism: Larotrectinib is an inhibitor of the tropomyosin receptor kinases (TRK), TRKA, TRKB, and TRKC. In a broad panel of purified enzyme assays, larotrectinib inhibited TRKA, TRKB, and TRKC with IC 50 values between 5-11 nM. One other kinase TNK2 was inhibited at approximately 100-fold higher concentration. TRKA, B, and C are encoded by the genes NTRK1, NTRK2, and NTRK3. Chromosomal rearrangements involving in-frame fusions of these genes with various partners can result in constitutively-activated chimeric TRK fusion proteins that can act as an oncogenic driver, promoting cell proliferation and...
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 9, 2025 Supplement 10 · Efficacy OrphanLetterLabel
- Mar 25, 2021 Supplement 4 · Efficacy OrphanLabelLetter
- Nov 26, 2018 Original approval · Type 3 - New Dosage Form · priority review Breakthrough therapyAccelerated approvalOrphanLabelReviewLetter
1 products under this application
- VITRAKVI · LAROTRECTINIB SULFATE EQ 20MG BASE/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Larotrectinib" as an intervention, any sponsor and status, largest first.
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02465060 · 6,452 participants (planned) · Start Aug 17, 2015 · Primary completion Dec 31, 2027
Drug: Adavosertib; Afatinib and 30 more · For: Advanced Lymphoma; Advanced Malignant Solid Neoplasm; Bladder Carcinoma and 49 more
Sites: Birmingham, Alabama; Fairhope, Alabama; Mobile, Alabama · 1,410 sites in all
National Cancer Institute (NCI)NIH
NCT03155620 · 1,377 participants · Start Jul 31, 2017 · Primary completion Mar 31, 2025
Drug: Ensartinib; Erdafitinib and 11 more · For: Advanced Malignant Solid Neoplasm; Ann Arbor Stage III Non-Hodgkin Lymphoma; Ann Arbor Stage IV Non-Hodgkin Lymphoma and 42 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Mesa, Arizona · 172 sites in all
- Molecularly Tailored Therapy in Advanced Pancreatic CancerPivotal-lookingNot yet recruiting
Herlev HospitalAcademic, hospital or other
NCT07802418 · 1,200 participants (planned) · Start Oct 2026 · Primary completion Jun 2031
Drug: Arm 1: Molecularly Tailored Therapy; Arms 2: Standard-of-Care Therapy and 1 more · For: Pancreatic Cancer
Sites: Aalborg, Denmark; Aarhus, Denmark; Herlev, Denmark · 4 sites in all
Fudan UniversityAcademic, hospital or other
NCT06195228 · 800 participants (planned) · Start Jan 1, 2020 · Primary completion Dec 31, 2026
Drug: dabrafenib plus trametinib with or without PD-1 antibody; entrectinib or larotrectinib with or without anti-PD-1 antibdoy and 4 more · For: Advanced Thyroid Cancer Patients Who Received Target Therapy
Sites: Fuzhou, China; Zhengzhou, China; Wuhan, China · 8 sites in all
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruiting
Fujian Medical UniversityAcademic, hospital or other
NCT07010393 · 335 participants (planned) · Start Jul 1, 2025 · Primary completion Dec 31, 2027
Drug: Dabrafenib; Trametinib and 9 more · For: Thyroid Neoplasms
Sites: Fuzhou, China
BayerBayer (BAYRY)
NCT02576431 · 215 participants · Start Sep 30, 2015 · Primary completion Sep 29, 2025
Drug: BAY2757556 (Larotrectinib, Vitrakvi) · For: Solid Tumors Harboring NTRK Fusion
Sites: Palo Alto, California; Santa Monica, California; Pembroke Pines, Florida · 98 sites in all
- A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in ChildrenActive, not recruiting
BayerBayer (BAYRY)
NCT02637687 · 154 participants · Start Dec 16, 2015 · Primary completion Jul 20, 2024
Drug: Larotrectinib (Vitrakvi, BAY2757556) · For: Solid Tumors Harboring NTRK Fusion
Sites: Los Angeles, California; Palo Alto, California; Orlando, Florida · 45 sites in all
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT06563999 · 120 participants (planned) · Start Nov 1, 2024 · Primary completion Nov 1, 2027
Drug: Sunvozertinib; Crizotinib and 7 more · For: Lung Cancer Stage III; Mutation
Sites: Guangzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dizziness62
- fatigue62
- drug ineffective61
- death52
- neuropathy peripheral45
- pain44
- disease progression38
- nausea38
- off label use38
- myalgia27
- vomiting27
- diarrhoea23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 97 |
| 2020 | 138 |
| 2021 | 147 |
| 2022 | 137 |
| 2023 | 138 |
| 2024 | 93 |
| 2025 | 100 |
| 2026 | 46 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Vitrakvi (Larotrectinib Sulfate)
2024 spending
$40.7M
Beneficiaries
180
1,096 claims
Per beneficiary
$225,932
$550.95 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $7,400,574 |
| 2021 | $17,432,265 |
| 2022 | $22,001,911 |
| 2023 | $29,548,699 |
| 2024 | $40,667,723 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Drilon A, Laetsch TW, Kummar S, et al. · N Engl J Med 2018 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Hong DS, DuBois SG, Kummar S, et al. · Lancet Oncol 2020 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer.
Hong DS, Xu RH, Shen L, et al. · ESMO Open 2025 · Clinical Trial, Phase I, Multicenter Study
- Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.
Doz F, van Tilburg CM, Geoerger B, et al. · Neuro Oncol 2022 · Clinical Trial, Research Support, Non-U.S. Gov't
- Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA's Health Technology Assessments.
Wagle JA, Flacke JP, Knoerzer D, et al. · Value Health 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Identification of genetically predicted DNA methylation markers associated with non-small cell lung cancer risk among 34,964 cases and 448,579 controls.
Zhao X, Yang M, Fan J, et al. · Cancer 2024 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Bayer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.